Thrombopoietin receptor agonist eltrombopag for advanced MDS or AML and severe thrombocytopenia: 12-week, randomized, placebo-controlled, phase 2 ASPIRE study

Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel; Universitatsklinikum Carl Gustav Carus, Dresden, Germany; Pavlov State Medical University, St. Petersburg, Russian Federation; Silesian Medical University, Katowice, Poland; Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; G. Papanikolaou General Hospital, Thessaloniki, Greece; Rambam Medical Center, Haifa, Israel; Marienhospital Stuttgart, Stuttgart, Germany; Azienda Ospedaliera Spedali Civili, Brescia, Italy; Sheba Medical Center, Ramat Gan, Israel; Hospital Virgen de la Victoria, Málaga, Spain; Novartis Pharmaceuticals Corporation, East Hanover, United States; AZ St-Jan Brugge AV, Brugge, Belgium

Haematologica. 2016;101((s1)):15-16.. s130.
Study details